Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.61 |
| ▸ | FNTB | P49356 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP4 | P49662 | 1/20 | 0.41 |
| ▸ | CASP5 | P51878 | 1/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17992570 | 1.00 | FNTA (0.61) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| SCHEMBL2120270 | 1.00 | FNTA (0.61) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| SCHEMBL8752386 | 1.00 | FNTA (0.61) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| Acetic Acid SCHEMBL2582613 | 0.99 | FNTA (0.60) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| SCHEMBL12156704 | 0.91 | FNTA (0.59) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| SCHEMBL25784983 | 0.91 | FNTA (0.51) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| SCHEMBL22038641 | 0.91 | FNTA (0.51) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| SCHEMBL10394983 | 0.89 | FNTA (0.49) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| SCHEMBL9069884 | 0.88 | NFKB1 (0.58) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| SCHEMBL9073533 | 0.87 | FNTA (0.51) | FNTAFNTBLMNASMN1; SMN2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106987542-B | Application of Arthrobacter simplex mutant strain in 1, 2-position dehydrogenation | 浙江神洲药业有限公司 | 2020-05-26 | — | — | CN | claimed |
| US-20230028248-A1 | METHOD FOR PREPARING 16ALPHA-HYDROXYPREDNISOLONE | ZHEJIANG SHENZHOU PHARMACEUTICAL COMPANY LIMITED (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-4116314-A1 | METHOD FOR PREPARING 16ALPHA-HYDROXYPREDNISOLONE | Zhejiang Shenzhou Pharmaceutical Company Limited (CN) | 2023-01-11 | — | — | EP | disclosed |
| CN-113666985-A | Preparation method of triamcinolone acetonide | 山东谷雨春生物科技有限公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3656385-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE | ReveraGen BioPharma, Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-2805720-B1 | Non-hormonal steroid modulators of NF-KB for treatment of disease | REVERAGEN BIOPHARMA INC (US) | 2019-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028248-A1 | METHOD FOR PREPARING 16ALPHA-HYDROXYPREDNISOLONE | HSD17B2, HSD11B1, CYP17A1 | FNTA 315/4885FNTB 1099/4885LMNA 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.